S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
New CBOE “special perk” helps traders target income every weekend (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
New CBOE “special perk” helps traders target income every weekend (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
New CBOE “special perk” helps traders target income every weekend (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
New CBOE “special perk” helps traders target income every weekend (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?

Vanda Pharmaceuticals Stock Price, News & Analysis (NASDAQ:VNDA)

$4.04
+0.08 (+2.02%)
(As of 12/6/2023 ET)
Compare
Today's Range
$3.95
$4.11
50-Day Range
$3.38
$4.58
52-Week Range
$3.30
$11.04
Volume
652,518 shs
Average Volume
790,740 shs
Market Capitalization
$232.43 million
P/E Ratio
19.24
Dividend Yield
N/A
Price Target
N/A

Vanda Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
3.55% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.77
Upright™ Environmental Score
News Sentiment
0.88mentions of Vanda Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.01) to ($0.46) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

385th out of 957 stocks

Biotechnology Industry

22nd out of 67 stocks


VNDA stock logo

About Vanda Pharmaceuticals Stock (NASDAQ:VNDA)

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

VNDA Stock Price History

VNDA Stock News Headlines

Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
Q3 2023 Vanda Pharmaceuticals Inc Earnings Call
Vanda Pharmaceuticals earnings preview: what Wall Street is expecting
Vanda Pharmaceuticals Q3 Earnings Preview
Vanda Pharmaceuticals (NASDAQ: VNDA)
See More Headlines
Receive VNDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2021
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/14/2024

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:VNDA
CUSIP
92165910
Employees
290
Year Founded
2002

Profitability

Net Income
$6.28 million
Pretax Margin
8.31%

Debt

Sales & Book Value

Annual Sales
$211.85 million
Cash Flow
$0.11 per share
Book Value
$9.32 per share

Miscellaneous

Free Float
53,102,000
Market Cap
$232.43 million
Optionable
Optionable
Beta
0.59

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report














VNDA Stock Analysis - Frequently Asked Questions

How have VNDA shares performed in 2023?

Vanda Pharmaceuticals' stock was trading at $7.39 on January 1st, 2023. Since then, VNDA stock has decreased by 45.3% and is now trading at $4.04.
View the best growth stocks for 2023 here
.

Are investors shorting Vanda Pharmaceuticals?

Vanda Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 2,040,000 shares, an increase of 21.4% from the October 31st total of 1,680,000 shares. Based on an average daily trading volume, of 1,300,000 shares, the days-to-cover ratio is presently 1.6 days.
View Vanda Pharmaceuticals' Short Interest
.

When is Vanda Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 14th 2024.
View our VNDA earnings forecast
.

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) released its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.20 by $0.06. The biopharmaceutical company earned $70.10 million during the quarter, compared to analyst estimates of $73.50 million. Vanda Pharmaceuticals had a trailing twelve-month return on equity of 2.19% and a net margin of 5.56%. During the same period in the previous year, the firm posted $0.11 earnings per share.

What ETFs hold Vanda Pharmaceuticals' stock?

ETFs with the largest weight of Vanda Pharmaceuticals (NASDAQ:VNDA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Horizon Kinetics Medical ETF (MEDX), iShares Neuroscience and Healthcare ETF (IBRN), iShares U.S. Pharmaceuticals ETF (IHE),

What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO?

12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com. Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Vanda Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Array Technologies (ARRY), Micron Technology (MU) and Novavax (NVAX).

Who are Vanda Pharmaceuticals' major shareholders?

Vanda Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Acadian Asset Management LLC (3.04%), Jacobs Levy Equity Management Inc. (1.68%), Federated Hermes Inc. (1.57%), Charles Schwab Investment Management Inc. (1.12%), Ameriprise Financial Inc. (1.10%) and Northern Trust Corp (0.98%). Insiders that own company stock include Aranthan Jones II, Gunther Birznieks, Joakim Wijkstrom, Kevin Patrick Moran, Melissa Young, Mihael Hristos Polymeropoulos, Phaedra Chrousos, Richard W Dugan, Stephen Ray Mitchell, Thomas Watkins and Timothy Williams.
View institutional ownership trends
.

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:VNDA) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -